Erratum: Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury (Circulation Research (2013) 112 (432-440) DOI: 10.1161/CIRCRESAHA.112.300755);Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury

Circulation Research

Volumn 112, Issue 3, 2013, Pages 432-440

  Yu, Zhou ^a   Ricciotti, Emanuela ^a   Miwa, Takashi ^a   Liu, Shulin ^a   Ihida Stansbury, Kaori ^b   Landersberg, Gavin ^c   Jones, Peter L ^b   Scalia, Rosario ^c   Song, Wen Chao ^a   Assoian, Richard K ^a   Fitzgerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

angioplasty and stenting; animal model of human disease remodeling; inflammation; leukotrienes; restenosis; smooth muscle cell; vascular injury

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BROXURIDINE; CYTOKINE; LEUKOTRIENE B4; SCLEROPROTEIN; TENASCIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BONE MARROW CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMORAL ARTERY; MACROPHAGE; MALE; MOUSE; NEOINTIMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 84873414539     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/RES.0000000000000113     Document Type: Erratum

References (31)

1. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871-1875.
2. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase- activating protein (FLAP) in murine acute inflammatory responses. J Exp Med. 1997;185:1065-1075.
3. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA. 2003;100:1238-1243.
4. Lötzer K, Funk CD, Habenicht AJ. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta. 2005;1736:30-37.
5. Knoerzer DL, Rapp SR, Goetz BD, Hanselman J, Butteiger D, Zhang LL, Garner PA, Turk JR, Broschat KO. Inhibition of 5-lipoxygenase pathway targets alone and in combination with statin therapy results in significant cholesterol lowering in atherosclerotic animal models. Arterioscler Thromb Vasc Biol. 2009;29:E25-E25.
6. Schoenberger SP. BLT for speed. Nat Immunol. 2003;4:937-939.
7. Bäck M, Bu DX, Bränström R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA. 2005;102:17501-17506.
8. Provost P, Borgeat P, Merhi Y. Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: effects of MK-886, a leukotriene biosynthesis inhibitor. Br J Pharmacol. 1998;123:251-258.
9. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase- activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005;293:2245-2256.
10. Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, Pasdar A, Grant SF, Whalley LJ, Hakonarson H, Thorsteinsdottir U, Kong A, Gulcher J, Stefansson K, MacLeod MJ. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet. 2005;76:505-509.
11. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239.
12. Shah SH, Hauser ER, Crosslin D, et al. ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. Atherosclerosis. 2008;201:148-154.
13. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg. 1994;81:1254-1269.
14. Willis AI, Pierre-Paul D, Sumpio BE, Gahtan V. Vascular smooth muscle cell migration: current research and clinical implications. Vasc Endovascular Surg. 2004;38:11-23.
15. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res. 1986;58:427-444.
16. Horwitz AR, Parsons JT. Cell migration-movin' on. Science. 1999;286:1102-1103.
17. Jeremy JY, Jackson CL, Bryan AJ, Angelini GD. Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty. Prostaglandins Leukot Essent Fatty Acids. 1996;54:385-402.
18. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, Omata M, Makuuchi M, Hirata Y, Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000;32:2097-2104.
19. Gallo R, Padurean A, Toschi V, Bichler J, Fallon JT, Chesebro JH, Fuster V, Badimon JJ. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation. 1998;97:581-588.
20. Hui Y, Ricciotti E, Crichton I, Yu Z, Wang D, Stubbe J, Wang M, Puré E, FitzGerald GA. Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation. 2010;121:2654-2660.
21. Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, Yeh C, Secreto A, Assoian RK, Rader DJ, Puré E. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest. 2001;108:1031-1040.
22. Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, Song WC. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am J Pathol. 2007;170:1258-1266.
23. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005;4:664-672.
24. Hallstrand TS, Henderson WR Jr. Leukotriene modifiers. Med Clin North Am. 2002;86:1009-1033, vi.
25. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, Feldman L, Bäck M. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and instent stenosis. Arterioscler Thromb Vasc Biol. 2009;29:518-524.
26. Poeckel D, Zemski Berry KA, Murphy RC, Funk CD. Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knockout mice. J Biol Chem. 2009;284:21077-21089.
27. Zhao L, Moos MP, Gräbner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004;10:966-973.
28. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ, Shih W. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120-126.
29. Yu Z, Crichton I, Tang SY, Hui Y, Ricciotti E, Levin MD, Lawson JA, Puré E, FitzGerald GA. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci USA. 2012;109:6727-6732.
30. Davis C, Fischer J, Ley K, Sarembock IJ. The role of inflammation in vascular injury and repair. J Thromb Haemost. 2003;1:1699-1709.
31. Angelini GD, Bryan AJ, Williams HM, Morgan R, Newby AC. Distention promotes platelet and leukocyte adhesion and reduces short-term